clinical trial · NCT06565689
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Excyte Biopharma Ltd·phase1·recruiting·n = 48
Relapsed or Refractory B-Cell Non-Hodgkin LymphomaYK012
brief summary
This study aims to provide a basis for further clinical development of YK012.
started
May 9, 2023
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Jul 17, 2026
detailed description
This study is the first-in-human clinical trial to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of YK012 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
official title
A Multi-center, Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol